Clinical trial
High-Density Atrial Mapping After Pulsed Field Ablation (PFA): Development of an Algorithm to Predict Atrial Fibrillation (AF) Burden in Participants With Paroxysmal AF (PAF) and Persistent AF (PsAF) Treated With the VARIPULSE™ PFA Catheter
NCT07788989 is registered in ClinicalTrials.gov with Biosense Webster, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- High-Density Atrial Mapping After Pulsed Field Ablation (PFA): Development of an Algorithm to Predict Atrial Fibrillation (AF) Burden in Participants With Paroxysmal AF (PAF) and Persistent AF (PsAF) Treated With the VARIPULSE™ PFA Catheter
- Lead sponsor
- Biosense Webster, Inc.
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- October 31, 2029
- Enrollment
- 2,300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.